Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

New Delhi [India]15 August (Memorial): Union Trade and Industry Minister Piyuh Goyal discussed strategies to increase competitiveness with the business representatives of the pharmaceutical industry and strengthen research and development activities.

“He had an inspiring interaction with the leaders of India’s pharmaceutical industry.

The meeting takes place at a time when the US increases the possibility of significant impacts on many sectors, except for the exempted tariffs and exempted tariffs. The Ministry is actively involved in industrial stakeholders to evaluate the potential impact of import tariffs and draw a strategic way forward.

Pharmaceuticals, electronic and semiconductors, energy products and some minerals, copper, timber, ingots and automobile components and automobile components are among the sectors that are exempted from tariffs.

In 2025, approximately 40 percent of India’s pharmaceutical exports were directed to the United States. India’s share of US in total drug imports was 6 percent in 2024.

According to the secondary market research analysis published by Bain and Company in 2025, India Pharmaceutical Exports ranked 11th globally in 2023 and made up 3 percent of total drug exports.

According to monthly trade data published by the Ministry of Commerce, it includes the main driving forces, engineering goods, electronic goods, jewels, drugs and drugs and organic and inorganic chemicals of goods in July 2025.

Data shows that drugs and drug exports increased from USD $ 2.33 billion in July 2024 to USD $ 2.66 billion in July 2025.

Company Sun Pharmaceutical, Dr. Large Indian pharmaceutical companies such as Reddy’s Laboratoies, Jepla, Biocon, Lupine, Glenmark Pharma and Zydus (Zydus Lifesciences) are exposed to US markets. (MOMENT)